An Open-Label, Randomized, Two-Way Crossover Study To Evaluate The Steady-State Effect Of Fesoterodine On The Pharmacokinetics And Pharmacodynamics Of A Single Supratherapeutic Dose Of Warfarin In Healthy Subjects.

NCT00914667 Phase 1 COMPLETED

This is an open-label, randomized, two-way crossover study to evaluate the steady-state effect of fesoterodine (8 mg QD) on the pharmacodynamics and pharmacokinetics of a single supratherapeutic dose of warfarin (25 mg) in healthy subjects.

Details

Lead sponsor	Pfizer
Phase	Phase 1
Status	COMPLETED
Enrolment	14
Start date	2009-07
Completion	2009-08

Conditions

• Urinary Bladder, Overactive

Interventions

• warfarin
• Warfarin plus Fesoterodine

Primary outcomes

• Cmax and AUCinf for both S- and R-warfarin — 8 days per period
• AUC_INR and INRmax — 8 days per period

Countries

United States